Wall Street analysts expect Clementia Pharmaceuticals (NASDAQ:CMTA) to report ($0.33) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Clementia Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.36) and the highest estimate coming in at ($0.28). The firm is scheduled to announce its next quarterly earnings results on Wednesday, May 23rd.
On average, analysts expect that Clementia Pharmaceuticals will report full year earnings of ($1.33) per share for the current financial year, with EPS estimates ranging from ($1.57) to ($1.18). For the next financial year, analysts anticipate that the company will post earnings of ($1.37) per share, with EPS estimates ranging from ($1.67) to ($1.25). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Clementia Pharmaceuticals.
A number of brokerages have issued reports on CMTA. Zacks Investment Research lowered Clementia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. B. Riley began coverage on Clementia Pharmaceuticals in a research report on Wednesday, March 28th. They issued a “buy” rating and a $25.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Clementia Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $26.60.
Institutional investors have recently bought and sold shares of the company. Orbimed Advisors LLC purchased a new stake in shares of Clementia Pharmaceuticals during the third quarter worth $176,082,000. JPMorgan Chase & Co. purchased a new stake in shares of Clementia Pharmaceuticals during the third quarter worth $10,937,000. Sectoral Asset Management Inc purchased a new stake in shares of Clementia Pharmaceuticals during the third quarter worth $512,000. Citadel Advisors LLC purchased a new stake in shares of Clementia Pharmaceuticals during the third quarter worth $2,061,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of Clementia Pharmaceuticals during the third quarter worth $729,000. 68.04% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ CMTA traded up $1.57 on Monday, reaching $16.72. The stock had a trading volume of 37,667 shares, compared to its average volume of 75,637. The firm has a market cap of $480.53 and a price-to-earnings ratio of -2.11. Clementia Pharmaceuticals has a 12-month low of $11.72 and a 12-month high of $20.15.
About Clementia Pharmaceuticals
Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. Its lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.